| __timestamp | AstraZeneca PLC | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 9136000 |
| Thursday, January 1, 2015 | 4646000000 | 5807000 |
| Friday, January 1, 2016 | 4126000000 | 5571000 |
| Sunday, January 1, 2017 | 4318000000 | 5366000 |
| Monday, January 1, 2018 | 4936000000 | 6337000 |
| Tuesday, January 1, 2019 | 4921000000 | 11347000 |
| Wednesday, January 1, 2020 | 5299000000 | 30419000 |
| Friday, January 1, 2021 | 12437000000 | 62176000 |
| Saturday, January 1, 2022 | 12391000000 | 52827000 |
| Sunday, January 1, 2023 | 8040000000 | 35049000 |
| Monday, January 1, 2024 | 10207000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for strategic planning. From 2014 to 2023, AstraZeneca PLC and Ligand Pharmaceuticals Incorporated have shown contrasting trends in their cost of revenue. AstraZeneca's cost of revenue surged by approximately 115% from 2014 to 2021, peaking in 2021 with a significant increase, before slightly declining in 2023. This reflects their aggressive expansion and investment in R&D. In contrast, Ligand Pharmaceuticals, a smaller player, experienced a more modest increase of around 284% over the same period, indicating a strategic focus on niche markets and partnerships. The data highlights AstraZeneca's robust growth strategy, while Ligand's steady rise underscores its adaptive business model. These insights provide a window into the financial dynamics of two distinct pharmaceutical giants, offering valuable lessons for investors and industry analysts alike.
Cost Insights: Breaking Down AstraZeneca PLC and Takeda Pharmaceutical Company Limited's Expenses
Cost Insights: Breaking Down AstraZeneca PLC and Regeneron Pharmaceuticals, Inc.'s Expenses
AstraZeneca PLC vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Bausch Health Companies Inc.
Analyzing Cost of Revenue: AstraZeneca PLC and Galapagos NV
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: United Therapeutics Corporation vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses